Association of high serum concentration of the third component of complement (C3) with pre-existing severe coronary artery disease and new vascular events in women

Széplaki, Gábor; Prohászka, Zoltán; Duba, J.; Rugonfalvi-Kiss, Szabolcs; Karádi, István; Kókai, Márta; Kramer, J.; Füst, George; Kleiber, Mónika; Romics, L; Varga, Lilian

doi:10.1016/j.atherosclerosis.2004.07.022

Cited by 89 publications

(63 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been previously reported that in RA, as well as in other inflammatory conditions, the presence of abnormally, pathologically elevated complement C3 levels may reflect the presence of an underlining inflammatory process (23). We can suggest that the relatively high amount of plasma C3 could be due to spill over from the joints probably reflecting an in situ over-expression or even to an abnormal production of complement proteins due to inflammation (24)(25). This could explain the reduction in complement C3 and C4 levels in the absence of complement activating cleavage fragments observed by us after treatment with TNF antagonists.…”

Section: Complement Disease Activity and Anti-tnf Treatmentmentioning

confidence: 77%

Complement System and Rheumatoid Arthritis: Relationships with Autoantibodies, Serological, Clinical Features, and Anti-TNF Treatment

Muzio

Perricone

Ballanti

et al. 2011

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

The first two authors contributed equally to this work Autoantibodies (rheumatoid factor, RF; anti-citrullinated-protein antibodies,ACPA) and complement system are involved in rheumatoid arthritis (RA). ACPA and anti-TNF agents are capable of in vitro modulating complement activity. We investigated the relationships between complement, autoantibodies, and anti-TNF treatment in vivo. One-hundred fourteen RA patients (89F/25M), diagnosed according to 1987 ACR criteria, and 30 healthy controls were enrolled. Serological analysis included ESR, CRP, complement C3, C4 and CH50, RF and ACPA (ELISA, cut-off>20U/ml). Split-products (SP) of C3 and B were studied by immunoelectrophoresis/counterimmunoelectrophoresis. Seventy-six patients started anti-TNF treatment and were studied at baseline and after 22 weeks. Disease activity was measured with DAS28 and response to therapy with EULAR criteria. At baseline, RA patients showed significantly higher levels of C3 and C4 than controls (C3 127.9±26.5 vs 1l0±25mgldl, P=O.0012; C4 29.7±10.2 vs 22.7±8.3mgldl, P=0.0003). No differences in C3, C4 and CH50 levels were observed between ACPA+ (n=76) and ACPA-(n=38) patients. After 22 weeks of anti-TNF, C3, C4 and RF were significantly reduced (P<0.003, <0.005 and <0.04, respectively) and RF changes showed negative correlation with CH50. SP of C3 and B were observed neither at baseline nor after 22 weeks. DAS28 significantly improved after 22 weeks. Patients showing higher baseline C3 or lower reduction of C3 levels after 22 weeks had a worse EULAR outcome (x2=22.793, P

show abstract

Section: Complement Disease Activity and Anti-tnf Treatmentmentioning

confidence: 77%

Complement System and Rheumatoid Arthritis: Relationships with Autoantibodies, Serological, Clinical Features, and Anti-TNF Treatment

Muzio

Perricone

Ballanti

et al. 2011

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

show abstract

“…Several clinical studies have demonstrated a correlation between serum C3 levels and the severity of atherosclerosis. Serum C3 was shown as a predictor of acute myocardial infarction (AMI) 15) and of new vascular events in women with severe coronary artery disease (CAD) 16) . Serum C3 levels have also been reported to be independently associated with atherosclerosis in patients with CAD 21) and, in that study, serum C3 was a better predictor than serum CRP.…”

Section: Discussionmentioning

confidence: 99%

“…The S-Cr was 0.85± 0.27 mg/dL, and the eGFR was 79.1±23.3 mL/ tory cytokine or adipokine. It has been reported that serum levels of C3 may serve as a predictor of future coronary events [15][16][17] and also the clinical prognosis after acute ischemic stroke 18) . C3 production is enhanced by inflammation and metabolic disorders.…”

Section: Background Characteristics and Laboratory Data Of The Ckd Pamentioning

confidence: 99%

Serum Complement C3 Predicts Renal Arteriolosclerosis in Non-Diabetic Chronic Kidney Disease

Kojima

Takei

Ogawa

et al. 2012

JAT

View full text Add to dashboard Cite

Aim: Complement C3 (C3) is one of the major mediators of inflammation. Serum C3 has been shown to be correlated with the presence of atherosclerosis. We examined whether the serum C3 level might be correlated with the severity of renal arteriolosclerosis in patients with chronic kidney disease (CKD). Methods: Non-diabetic CKD (stages 1-3) patients who underwent renal biopsy were enrolled in this study. Renal arteriolosclerosis was defined by the presence of hyaline changes and vessel wall thickening in the renal biopsy specimens. We examined whether the serum C3 level might be correlated with the severity of renal arteriolosclerosis in CKD patients.

show abstract

“…Previously, a C3 cutoff point of 1.8 g l À1 has been used to differentiate varying levels of coronary artery disease and vascular events. 60 Similarly, in boys with high C3 levels (X1.8 g l À1 ), no difference was found in average resistin levels and no group-specific correlation could be made between resistin and obesity, insulin resistance or MetS markers. However, significant positive correlations were found in girls between resistin and C3 (P ¼ 0.009) or CRP (P ¼ 0.004) after puberty onset (Tanner stages 2-5).…”

Section: Relations Between Resistin and Inflammationmentioning

confidence: 95%

Serum resistin correlates with central obesity but weakly with insulin resistance in Chinese children and adolescents

Fisette

et al. 2009

Int J Obes

View full text Add to dashboard Cite

Objective: Resistin has been linked with obesity and hypothesized as a potential marker of insulin resistance in addition to being linked with acute inflammation. However, these links are still highly controversial in humans. Our goal was to examine resistin levels in relation to obesity, insulin resistance and inflammation markers in a large population of Asian children and adolescents. Methods: Children and adolescents (n ¼ 3472) aged 6-18 years, boys (n ¼ 1765) and girls (n ¼ 1707), were assessed for body size parameters, pubertal development, blood lipids, glucose, insulin, resistin, C-reactive protein (CRP), adiponectin and complement C3 (C3) levels. Results: Resistin increased with central obesity in both genders but not with simple adiposity in boys. Several markers associated with central obesity correlated in a gender-specific fashion with plasma resistin. Waist circumference, fat-mass percentage, waistto-height ratio and body mass index (BMI) positively correlated with resistin in both genders. Blood lipids such as triglycerides, nonesterified fatty acids (NEFA) and low-density lipoprotein cholesterol, diastolic and systolic blood pressure correlated positively with resistin in boys. NEFA, high-density lipoprotein cholesterol (negatively) and inflammation markers, such as CRP and C3, positively correlated with resistin in girls. There was no correlation between resistin and adiponectin, and no association of adiponectin with resistin quintiles in either boys or girls. In both boys and girls, resistin tended to decrease with age, with girls having higher levels than boys. Few indices of insulin resistance were linked with plasma resistin in either gender. Conclusion: In this population, plasma resistin levels are a weak biochemical marker of metabolic dysfunction defined by central obesity, adiposity and inflammation and does not predict insulin resistance. Only a small proportion of resistin variation can be explained by factors related to metabolic syndrome, suggesting that resistin is not strongly implicated in a concentrationdependent fashion in any of the examined pathologies.

show abstract

Association of high serum concentration of the third component of complement (C3) with pre-existing severe coronary artery disease and new vascular events in women

Cited by 89 publications

References 28 publications

Complement System and Rheumatoid Arthritis: Relationships with Autoantibodies, Serological, Clinical Features, and Anti-TNF Treatment

Complement System and Rheumatoid Arthritis: Relationships with Autoantibodies, Serological, Clinical Features, and Anti-TNF Treatment

Serum Complement C3 Predicts Renal Arteriolosclerosis in Non-Diabetic Chronic Kidney Disease

Serum resistin correlates with central obesity but weakly with insulin resistance in Chinese children and adolescents

Contact Info

Product

Resources

About